Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NTRC 12026-0

Next Previous
Drug Profile

NTRC 12026-0

Alternative Names: BTK inhibitor - Crossfire Oncology; NTRC-12026-0

Latest Information Update: 23 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NTRC Therapeutics
  • Developer Crossfire Oncology
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 11 Oct 2023 Crossfire Oncology plans a first in human trial for Haematological malignancies in second half of 2024 (Crossfire Oncology pipeline, October 2023)
  • 03 Jan 2023 Bruton tyrosine kinase inhibitors - NTRC Therapeutics is available for licensing as of 03 Jan 2023. https://www.ntrctx.com/ntrc-our-science/ (NTRC Therapeutics website, January 2023).
  • 03 Jan 2023 Preclinical trials in Haematological malignancies in Netherlands (unspecified route) prior to January 2023 (NTRC Therapeutics pipeline, January 2023).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top